Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights.
Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
The introduction of biomarker has shown to have critical role in the diagnosis and management of cancer. In advancement towards precision medicine, the field of cancer biomarker discovery has rapidly expanded over the last few decades. This has been developed by advances in technologies and approaches including next generation sequencing, mass spectrometry, circulating tumor cells, and cell-free DNA. The discovery and use of specific prognostic and predictive biomarkers have enabled the application of targeted precision therapies to specific molecular subgroups of patients likely to gain benefit. Within breast cancer, recent biomarker discovery efforts have led to the identification and development of several prognostic and predictive biomarkers including multigene signatures.
Till date, three most important biomarkers for breast cancer are estrogen receptor (ER), progesterone receptor (PR) and a receptor called HER2. The levels of these markers can influence how a person with breast cancer is treated in the clinic. Despite these advances, there is still an important clinical need for the development and validation of novel biomarkers with greater sensitivity, specificity, and clinical utility. Among all targeted therapies, immunotherapy is gaining considerable interest for the management of breast cancer. So far, the typical biomarkers like PD-L1 expression and the numbers of immune cells in the tumor are used for identifying potential patients for the therapy.
The high adoption rates of immunotherapeutic approaches in breast cancer management has surged the further research and development activities in breast cancer biomarker market. Currently, large number of ongoing clinical trials is validating the role of novel biomarkers for breast cancer immunotherapy approaches. Recently a study demonstrated that a molecule called the Major Histocompatibility Complex Class II protein (MHC-II), has the potential to be a predictor of immunotherapy benefit with two types of breast cancer including early-stage, triple negative breast cancer (TNBC) and high-risk, oestrogen receptor-positive breast cancer (HR+) when expressed on breast cancer cells. The findings of the association with response in early-stage high-risk HR+ patients suggests that MHC-II may be a useful tool in a broader context for breast cancer and this area would benefit from further study.
As per our report findings, the global breast cancer antibodies market will surpass US$ 15 Billion by 2028. The increasing prevalence of breast cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various breast cancer subtypes. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for breast cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high breast cancer biomarkers market revenue in the coming years.
Although the market is poised to grow in the forthcoming years, the market faces several challenges in terms of reimbursement policies supported by the government. This is further attributed to the high cost of breast cancer treatment, especially in developing nations. Nevertheless, government support in spreading awareness about breast cancer, and the availability of treatment options for the same are likely to create lucrative growth opportunities for the market in the forthcoming years.
Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market’s future growth.
Contact:
Preeti Dureja
Research Partner
Biomarkers Insights
sample@biomarkersinsights.com